ELISA for sarcopenia
Sarcopenia is defined as the loss of skeletal muscle mass and strength that can occur with advancing age. The current diagnosis of the disease is by dual-emission X-ray absorptiometry (DXA) scan, which measures lean body mass (LBM) in combination with functional tests. This cumbersome technique provides no information on the underlying cause of the loss of LBM. A novel biomarker is now available to identify the subgroup of patients (40%), whose sarcopenia is caused by excessive neurotrypsin activity. The NTCAF ELISA test has initially been developed for research purposes to aid the development of a treatment for the condition and could have potential as a companion diagnostic.
Supplier: Neurotune AG
Website:
